Clinical trials
Phase 1 Neoplasms trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
80 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 14 |
| 2014 | 11 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 5 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 57 |
| Active, not recruiting | 11 |
| Terminated | 6 |
| Recruiting | 3 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 12 |
| AstraZeneca | 9 |
| Sanofi | 7 |
| AbbVie | 5 |
| Amgen | 5 |
| Bristol-Myers Squibb | 3 |
| Hoffmann-La Roche | 3 |
| Janssen Research & Development, LLC | 3 |
| Novartis Pharmaceuticals | 3 |
| Bayer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 80 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Colorectal Neoplasms | 10 |
| Neoplasm Metastasis | 9 |
| Breast Neoplasms | 6 |
| Ovarian Neoplasms | 6 |
| Triple Negative Breast Neoplasms | 6 |
| Carcinoma, Hepatocellular | 5 |
| Head and Neck Neoplasms | 5 |
| Squamous Cell Carcinoma of Head and Neck | 5 |
Trials
Showing 1 to 25 of 80. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.